| This article has been cited by |
| 1 | Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review | |
| Shashikant Sharma,Tanishq Sharma,Somdutt Prasad,Mahesh Gopalakrishnan,Alok Chaturvedi |
| Ophthalmology and Therapy.2021;10(3)431 |
| [DOI] |
|
| 2 | Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study | |
| Debdulal Chakraborty,Sabyasachi Sengupta,Soumen Mondal,Subhendu Boral,Arnab Das,Tushar Kanti Sinha,Ranabir Bhattacharya,Ritobroto Maitra |
| Ophthalmology and Therapy.2022;11(2)629 |
| [DOI] |
|
| 3 | Insurance coverage for intravitreal injections in India—The road ahead | |
| Raja Narayanan,Sabyasachi Sengupta |
| Indian Journal of Ophthalmology.2021;69(5)1027 |
| [DOI] |
|
.png "Santen")
